coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Knowsley Central And South PCN, Knowsley (LAD) · Health Inequalities Profile

    PCN U71643 · NHS Cheshire and Merseyside Integrated Care Board · 11 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    70,346

    Registered population

    60.1% aged 18–64

    18.7%

    Aged 65+

    ICB 19.0% · England 17.9%

    5.8%

    Ethnic minority (non-White)

    2.3% Asian · England 9.6%

    46.3%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~30,342

    Core20 residents (est.)

    Resident basis; registered basis ~31,813 · see page 3

    12,340

    Hypertension register

    +5.75% in 3 yrs · England +5.60%

    741

    SMI register

    37.8% of Knowsley (LAD)'s

    2,245

    COPD register

    Reviews +17.23% in 3 yrs

    Forecast to 2030

    14,312

    Hypertension patients, 2030

    +1,972 on today

    71.3%

    QRISK ≥20% on statins, 2030

    +2.29pp over 3 yrs

    5.1%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    -3.5%
    Learning disability and COPD registers contracted.

    From 2023 to 2025, learning disability (-3.5% vs England +5.4%) and COPD (-3.4% vs +2.6%) prevalence fell, which may reflect unverified coding gaps.

    80.4%
    Pre-school MMR and asthma reviews trail.

    Age-5 MMR dose 2 is 80.4% (below the 95.0% target by 14.6 pp) and asthma reviews reach 63.2% (England 65.7%; 1,673 unreviewed).

    72.3%
    Adult blood pressure, COPD and screening.

    Hypertension control reaches 72.3% (England 70.3%), alongside 77.6% COPD annual reviews (England 76.4%) and 72.5% cervical screening (England 66.8%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Registered list of 70,346 has higher child and older cohorts than England

    Knowsley Central and South PCN covers 70,346 registered patients across member practices. Children aged 0-17 comprise 21.1% (14,859 patients), in line with Knowsley LAD (21.1%) and above NHS Cheshire and Merseyside ICB (19.2%) and England (19.6%). Patients aged 65+ represent 18.7% (13,186 patients), above the LAD (16.9%), below the ICB (19.0%), and above England (17.9%). Census usual residents are 94.2% White (LAD 95.3%, ICB 93.0%, England 81.1%), with a 5.8% ethnic minority share; these area figures do not reflect registered-patient ethnicity. Projected list growth is 2.8% to 2030 via an unverified model.

    Age profile

    0–1721.1%
    18–6460.1%
    65+18.7%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White94.2%
    Asian2.3%
    Mixed1.9%
    Black1.0%
    Other0.6%

    Older people · falls rows are Knowsley (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Knowsley LA)2,7842,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)83.8%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)58.1%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Knowsley LA)1,4401,0219552024/25
    Falls deaths, all ages, per 100,000 (Knowsley LA)23.118.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation reaches 46.3% PCN-wide but spans a 70.2 pp practice range

    Across the PCN, Core20 share is 46.3% (average IMD decile 3.9), below Knowsley (52.5%) but above the ICB (31.9%) and England (21.0%). Practice rates span 70.2 pp, from 17.4% at Roby Medical Centre to 87.6% at Stockbridge Village Hc. Modelled practice rates weight to 45.2%, a 1.05 pp discrepancy versus the PCN rate. Stockbridge Village Hc has the highest share (87.6%) and estimated volume (7,488 patients), followed by Dinas Lane Medical Centre (53.3%, 5,432 patients). Addressing both high-concentration practices and large-volume cohorts requires differentiated outreach.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Stockbridge87.6% · 7,488 patients
    Longview87.2% · 3,358 patients
    Nutgrove Villa63.8% · 2,401 patients
    Dinas Lane53.3% · 5,432 patients
    Cedar Cross41.8% · 2,113 patients
    Dr M Suares'36.4% · 1,950 patients
    Tarbock34.6% · 1,907 patients
    Park House28.9% · 2,220 patients
    Prescot28.1% · 2,305 patients
    Hollies25.5% · 1,643 patients
    Roby17.4% · 996 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    741

    SMI register

    1.08% recorded prevalence

    445

    Learning disability register

    0.65% recorded prevalence

    32

    Care homes, 1,380 beds

    In the PCN catchment

    11.5%

    Provide unpaid care

    Knowsley (LAD), Census 2021

    The PCN records 741 severe mental illness patients (1.1%, England 1.0%) and 445 learning disability patients (0.7%, England 0.6%), alongside 32 catchment care homes (1,380 beds). Knowsley LAD has an 11.5% unpaid care rate and 14 rough sleepers, which cannot be extrapolated to GP lists. Recorded SMI and learning disability prevalence exceed national rates, but crude prevalence does not establish unmet need or care home resident caseloads.

    Severe mental illness: physical health checks

    SMI recorded prevalence is 1.1% (England 1.0%). Annual blood pressure checks reach 84.9% (England 83.4%) and BMI recording reaches 85.5% (England 82.1%, Knowsley 89.8%). Missing health check elements are uncaptured, so completed comprehensive checks cannot be inferred.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    12,340

    Hypertension register

    +5.75%

    Register growth, 3 yrs

    Knowsley (LAD) +5.44% · England +5.60%

    +4.74pp

    BP control, under 80

    ≤140/90 · +4.30pp aged 80+

    +1,972

    More patients by 2030

    Forecast 14,312 (20.04%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 17.9% (12,340 patients), above England (15.2%), Knowsley (16.7%) and the ICB (16.8%), though crude QOF rates do not confirm case-finding completeness and the implied base differs from the registered list of 70,346. Annual blood pressure monitoring reached 90.5% (England 90.0%), and patients treated to target reached 72.3% (England 70.3%, ICB 69.1%). Control in patients aged under 80 reached 69.5% (England 67.8%), while three-year prevalence rose +5.8% (England +5.6%). Unverified projections indicate register demand could reach 14,312 patients by 2030, an addition of 1,972 patients. Strong blood pressure control above national rates protects cardiovascular outcomes, though managing an expanding cohort will require sustained clinical capacity.

    Lipids and statins

    While QRISK ≥20% lipid therapy coverage reaches 66.4% (England 63.6%), three-year growth rose only +3.6% against +6.2% in England. Secondary-prevention diabetes statin therapy fell 0.4% (England +1.0%). Trailing therapy growth behind national rates highlights an opportunity to review recall protocols for high-risk patients.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026152,574£1.70£1.71£1.86£259,376
    Cardiovascular (all), 2025211,272£4.52£4.37£3.33£954,949

    In 2026, lipid-regulating drugs cost £1.70 per item across 152,574 items (annual spend £259,376), compared with £1.86 in England, £1.63 in Knowsley (LAD), and £1.71 in the ICB, representing £24,412 less than at England's unit cost. Lower unit cost than England could reflect local formulary choices, providing an opportunity to expand lipid therapy coverage without disproportionate expenditure.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +16.72%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +2.53%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 3.3% (England 1.9%), though its register fell 3.4% over three years (England +2.6%), while COPD reviews reach 77.6% (England 76.4%). Asthma prevalence is 7.1% (England 6.6%, 4,542 patients), but annual reviews trail England at 63.2% (England 65.7%), leaving an estimated 1,673 unreviewed patients. Paediatric asthma prescribing reaches 2,939 items per 1,000 aged 5-19, well above England (1,488). High prescribing alongside lower review completion may reflect unverified recall gaps testable by clinical audit.

    Cancer register and children's immunisation

    The cancer register records 3,017 patients (4.4% prevalence vs England 3.8%). In childhood immunisations, MMR dose 2 coverage at age 5 reaches 80.4% (ICB 84.4%, England 82.8%), trailing the 95.0% target by 14.6 pp, with a 10.1 pp drop from dose 1 (90.5%). At 24 months, 6-in-1 coverage is 85.5% (England 92.2%). Slower second-dose completion leaves cohort immunity vulnerable and warrants systematic call-recall follow-up.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months88.0%

    England 91.0%

    6-in-1 complete primary course at 24 months85.5%

    England 92.2%

    MMR dose 1 at 24 months84.6%

    England 88.3%

    MMR dose 2 at age 580.4%

    England 82.8%

    4-in-1 pre-school booster at age 581.0%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    In 2022, 55.5% of cancers with a known stage in NHS Cheshire and Merseyside ICB (7,482 of 13,490) were diagnosed at stage 1 or 2 (England 55.3%), a distance of -19.5 pp to the 75.0% national ambition by 2028, requiring about 2,640 extra early-stage cases annually. Known-stage share was 72.8% (13,490 of 18,522 cancers; England 67.0%). In the PCN, cancer prevalence is 4.4% (3,017 patients), with three-year growth of +7.7% (England +9.0%). Cervical screening reaches 72.5% (England 66.8%) and breast screening reaches 72.4% (England 69.9%). Staging describes the ICB system, not PCN performance.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Mersey and West Lancashire Teaching Hospitals NHS Trust, 77.9596% of patients met the 62-day referral to treatment standard against the 85.0% standard (distance -7.0 pp; ICB 76.232%, distance -8.8 pp). For the 28-day faster diagnosis standard, the trust achieved 72.3923% against the 75.0% standard (distance -2.6 pp; ICB 77.2451%, distance 2.2 pp). On the 31-day combined treatment standard, the trust reached 95.4621% against the 96.0% standard (distance -0.5 pp; ICB 95.7087%, distance -0.3 pp). These hospital figures reflect acute provider flow rather than PCN referral performance.

    Pathways within standard (%)Mersey and West LancashireLiverpoolNorth Cheshire and MerseyCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)72.3975.4780.2177.2579.32
    31-day treatment (96%)95.4690.5198.1795.7192.50
    62-day referral to treatment (85%)77.9673.2683.6776.2371.16
    Diagnostic waits over 6 weeks (%)Mersey and West LancashireLiverpoolNorth Cheshire and MerseyEngland
    MRI14.046.420.5321.40
    CT13.080.712.329.92
    Echocardiography34.8812.5528.0428.48
    Colonoscopy18.0433.1415.9830.83
    Gastroscopy18.1744.9920.2429.02
    All 15 DM01 tests21.1711.506.3423.14
    Community services activityKnowsley residentsCheshire and Merseyside ICB
    Care contacts45,655541,280
    Referrals8,47597,150
    Patients with a contact12,490146,240

    Community services (residents of Knowsley), Jun 2026 (provisional). In the provisional Jun 2026 Community Services Dataset, adults aged 65 and over accounted for 57.9% of contacts among Knowsley borough residents (26,435 of 45,655 total contacts). These data reflect borough-level community activity and cannot be attributed directly to PCN registered patients.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Roby10617.487.4%82.7%95.9%
    Tarbock11134.685.0%58.8%93.3%
    Cedar Cross12341.863.4%75.7%89.7%
    Nutgrove Villa12863.889.0%73.7%89.6%
    Prescot11128.187.5%77.0%86.2%
    Dr M Suares'11136.467.6%75.0%84.5%
    Longview8787.270.6%78.2%83.1%
    Hollies11425.554.8%73.5%77.2%
    Stockbridge11087.631.9%74.8%73.6%
    Dinas Lane9653.327.7%81.2%73.4%
    Park House10828.932.0%71.1%69.0%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNKnowsley (LAD)AssetPCNKnowsley (LAD)
    Care homes (catchment)32 (1,380 beds)n/aSchools (catchment)117n/a
    Children's centres1015Places of worship3748
    Libraries43Primary schools (LA maintained)2432
    Primary academies1213Special schools12

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Asthma review and prescribing recall

    Annual asthma reviews reach 63.2% against 65.7% in England across a 4,542-patient register, leaving an estimated 1,673 patients without a recorded review in 12 months. For discussion: practices could run a single-template asthma recall audit prioritising unreviewed patients and reviewing inhaler prescribing alongside after-school review slots. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    COPD and learning disability register audit

    Over 2023 to 2025, COPD prevalence fell 3.4% (England +2.6%; modelled gap -912 to +271 patients) and learning disability fell 3.5% (England +5.4%; gap -32 to +29). For discussion: practices could audit clinical records for patients with repeated respiratory prescribing or historical learning disability codes missing from active QOF registers. Low cost, quick to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    Pre-school MMR second dose recall

    Age-5 MMR dose 2 coverage in Q1 2025/26 is 80.4% (ICB 84.4%, England 82.8%; cohort 189), 14.6 pp below the 95.0% target and 10.1 pp below dose 1 (90.5%). For discussion: practices could run targeted call-recall audits for children due their second MMR dose and offer flexible clinic times. Moderate effort to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Paediatric primary care capacity review (p2)Aged 0-17Medium Term Planning Framework 2026 · Neighbourhood health frameworkPCN
    Two-track Core20 allocation (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI health check review (p4)SMI register with a BMI recorded in the last 12 monthsMHIS · From Harm to HopePCN
    Sustain hypertension control pathways (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    MMR second dose recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sustain screening coverage (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Option 1 · Asthma review and prescribing recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Option 2 · COPD and learning disability register audit (p12)COPD register · COPD: QOF prevalence · Learning disability register75% annual health checks (Network Contract DES) · Oliver McGowanPCN
    Option 3 · Pre-school MMR second dose recall (p12)MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15